共同的初级终点指标为总生存率和无进展生存率。
Coprimary end points were rates of overall and progression-free survival.
研究人员提到，在两组中总生存期和无进展生存也没有差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
因此，替代终点如反应率和无进展生存率被普遍接受，尽管各方意识到风险所在。
Thus, surrogate endpoints like response rate and progression-free survival are commonly accepted, although all parties involved realize the risk involved.
主要指标是总生存期，次要指标包括无进展生存期(PFS)和客观反应率(ORR)。
The primary endpoint was overall survival, and secondary endpoints included PFS and objective response rate (ORR).
在确诊时的转化预示相对较好的预后，5年无进展生存率和总生存率分别达到66%和88%。
Transformation at the time of diagnosis portends a more favorable prognosis with 5-year PFS and OS rates of 66% and 88%, respectively.
主要研究终点为无进展生存（PFS），次级研究终点包括客观有效率、总生存和安全性。
The primary end point was progression-free survival; secondary end points included the objective response rate, overall survival, and safety.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
应用推荐